Skip to main content
The BMJ logoLink to The BMJ
. 2018 May 23;361:k2295. doi: 10.1136/bmj.k2295

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

PMCID: PMC5965379  PMID: 29793960

The prices quoted for the threshold analysis at the end of the cost effectiveness results section and in the table of Appendix 2 of this Research paper (BMJ 2017;359:j5058, doi:10.1136/bmj.j5058) are incorrect. The authors found that, to be more cost effective than apixaban, dabigatran’s price would have to reduce from an annual cost of £801.76 to £487.86, edoxaban would have to reduce from £801.76 to £222.93, and rivaroxaban would have to reduce from £766.52 to £201.47. A substantial discount is therefore necessary for these direct acting oral anticoagulants to become more cost effective than apixaban, but negative prices are not necessary.


Articles from The BMJ are provided here courtesy of BMJ Publishing Group

RESOURCES